drugset
drugset / Trial / NCT01298219

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219 ↗

Phase 3 Completed 439 enrolled Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.

Timeline

Start
2010-12
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 24 ug Oral

Indications

opioid-induced constipation